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For the past several years we have been working with models of benzene distribution and metabolism, principally in the rat, but more recently in
humans. Our biologically related objectives have been primarily to assist our laboratory-based colleagues in their quest for understanding of the
mechanisms by which benzene exerts its toxic action. A secondary goal has been to develop or adapt models useful in risk assessment
applications. We have also had methodological goals that relate to applications of sensitivity analysis on the one hand, but more fundamentally to
the connection between experimental data and model structure and parameterization. This paper presents an overview of our work in these areas
- Environ Health Perspect 102(Suppl 11):61-6 (1994)
Key words: modeling, benzene distribution, benzene metabolism, rats, human
Introduction
The postulate underlying much of our
work is that the construction and interpre-
tation ofmathematical models ofbiological
systems must recognize the population
variability inherent in the processes under
analysis. In our work, this has been realized
in two ways. We assign statistical distribu-
tion functions to the constant parameters
ofthe model to reflect population variabil-
ity in their values. Second, in much of our
work we judge the adequacy of a particular
simulation not by a continuous measure of
goodness of fit to laboratory or field data,
but by a binary outcome index which
reflects our judgment that the simulation is
or is not adequately representative of the
data. There is obviously a subjective aspect
to the judgment of the adequacy of a par-
ticular simulation, but we feel that the
benefits gained outweigh the costs.
Because many of the generally interest-
ing results of our work arise from this basic
analytical procedure, it is necessary to give
a somewhat more complete explanation of
the process through example, as well as to
give some further practical justification of
its features. The first model that we
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Figure 1. Schematic representation of the physiologic
model used to simulate the distribution of benzene.
Symbols: V, volumes; F, flows; P, partition coefficients;
VM., Km, Michaelis-Menten parameters; Kelp, metabo-
lite excretion rate;Aing, absortion rate.
worked with extensively described the dis-
tribution ofbenzene in Fischer rats. It is a
five-compartment physiologically based
pharmacokinetic (PBPK) model with
Michaelis-Menten terms describing the
transformation of benzene into its first
metabolites in the liver and the bone mar-
row. The general structure is shown in
Figure 1.
In our analysis ofthis model, we chose
ranges that define the limits of uniform
distributions for each ofthe parameters or
their scaling variables. To take into
account known structural dependencies
between the parameters, we made many of
them a function ofbody weight. This was
accomplished by defining three body
weight scaling functions, each of which
contained a scaling coefficient that was
assigned a range; this was also the case for
the unscaled model parameters. The ranges
for all 26 variables were selected to include
values reported in the literature for adult
rats. Monte Carlo simulations were used to
study the effects ofvariability in the model
parameters on its output. The parameters
were sampled uniformly or log-uniformly
from their ranges.
The model was evaluated against data
from three different sets ofexperiments in
what one might term a mini-metaanalysis
(1). All three experiments were performed
on male Fischer-344 rats. In the first set of
experiments, carried out by Rickert et al.
(2), rats were exposed to benzene through
inhalation. These experiments provide
extensive information about the kinetics of
benzene in blood, fat, bone marrow, and
exhaled air. The tissue concentrations were
recorded both during and after exposure.
Three rats were placed in an inhalation
chamber for a series ofexposure intervals.
At the end of each exposure interval, the
rats were killed, and the concentration of
benzene in the fat, blood, and bone mar-
row was measured.
The second two sets of experiments
were performed by Sabourin et al. (3,4). In
one set, rats were exposed to benzene
through inhalation. For each dosing level,
they were exposed by nose only for 6 hr,
and the total amount of benzene exhaled
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and the total amount of metabolites
excreted were obtained for the following 56
hr. In the other set ofexperiments, the rats
were exposed through gavage also at vari-
ous dosing levels. For each dosing level, the
total amount of benzene exhaled and the
total amount of metabolites excreted were
measured for the following 48 hr.
Before turning to the mini-metanaalysis,
it is instructive to consider first the kind of
information given by the Monte Carlo
experiments in contrast to the more usual
analysis in which most ofthe model para-
meters are fixed at biologically plausible val-
ues before a few important parameters are
adjusted to give a best fit to the experimental
data, typically those dealing with metabo-
lism. We carried out such a study (5) using
the results ofthe benzene modeling work of
Travis et al. and Medinsky et al. (6-8) to
compare to our own results, in which we
employed parameter distributions rather
than fixed values. Our model was struc-
turally similar to the Travis and Medinsky
models (their parameter values were always
within the ranges used in our Monte Carlo
simulations). The comparisons used the log-
likelihood function as a continuous measure
ofgoodness offit between the model predic-
tions and the experimental data points for
the Travis model and parameter set; for that
of Medinsky; and then for each of 1000
Monte Carlo simulations for our own
model. Figure 2 shows a plot in which each
experimental data point is plotted against its
simulated value for all the data in the
Rickert experiments. Not surprisingly, the
best Monte Carlo run gives a better overall
fit than either the Travis or Medinsky mod-
els, since the best Monte Carlo fit is, in
effect, the result of an optimizing search.
The same outcome can be seen for the
Sabourin inhalation and gavage data in
Figure 3.
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Figure 2. Predictions made using three published mod-
els, versus observed values of the data points obtained
during Rickert et al. (2) experiments. For a perfect fit, the
points would fall on the identity line. The best Monte
Carlo simulation lies the closest to the identity line
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Figure 3. Predictions made using three published
models, versus observed values of the data points
obtained during Sabourin et al. (3,4) experiments. For
a perfect fit, the points would fall on the identity line.
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Figure 6. Percentage of the administered dose
excreted as metabolites by Fischer-344 rats, during
the 48 hr following benzene gavage. The open circles
represent the experimental data (± SD) of Sabourin et
al. (3,4) The profiles obtained using three published
models are given. The shaded area encloses the
results of the 200 Monte Carlo simulations of highest
log-likelihood.
ments ofthe metabolic parameters Km and
max
The Pass-Fail Criterion of Fit
A worrying feature inherent in the forego-
ing studies is the implicit reliance placed on
the mean values ofvery small numbers of
observations per data point. Given the vari-
ability to be expected in these mean values,
it is important to keep in mind that the
measure ofgoodness offit ofthe model to
these data is itself a random variable of
unknown distribution. In past studies, this
same uncertainty has led us to choose an
alternative to a continuous measure of
goodness offit. Our alternative is to formu-
late a set ofcriteria which attempt to define
the adequacy ofa simulation as either hav-
ing captured the essence ofthe data or not
having done so. We have, in effect,
explored the notion ofa binary criterion of
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Figure 4. Benzene concentration in the fat of Fischer-
344 rats, during and after a 6 hr exposure to 490 ppm
benzene in the air. The open circles represent the
experimental data (± SD) of Rickert et al. (2). The time
profiles obtained using three published models are
given. The shaded area encloses the results of the 200
Monte Carlo simulations of highest log-likelihood.
Somewhat more instructive are the next
figures showing the time course ofseveral
measured variables. Figure 4 shows ben-
zene in the fat for the Rickert data, where
the shaded area encloses the trajectories of
the 200 best Monte Carlo runs, all of
which had lower log-likelihoods that either
the Travis or Medinsky models. Similarly,
Figure 5 shows the benzene concentration
in the venous blood for the Rickert experi-
ment. It can be seen that the Travis model
shows a much better fit than the best
Monte Carlo simulation, which points out
that the best fit overall, as measured by the
log-likelihood function, does not guarantee
a best or even a good fit to a particular sub-
set of the total data set. Finally, Figure 6
shows the percentage of the administered
dose excreted as metabolic products during
the 48 hr following benzene gavage in the
Sabourin experiment. Here, all three mod-
els give similar results, presumably because
Travis and Medinsky paid particular atten-
tion to fitting these data in their adjust-
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Table 1. Definition of additional criteria used for evaluating the results for Rickert's experiments.
Variable Observation time Range, % Reference time, hr
(During 8-hr exposure)
Bone marrow concentration 0.5 15.0-55.0 6.0
Fat concentration 2.0 5.0-35.0 6.0
Venous blood concentration 1.5 30.0-70.0 6.0
(After 6-hr exposure)
Bone marrow concentration 6.5 20.0-60.0 6.0
9.0 0.02-5.0 6.0
Fat concentration 8.0 30.0-70.0 6.0
15.0 1.0-10.0 6.0
Venous blood concentration 6.5 30.0 -70.0 6.0
10.0 1.0-10.0 6.0
Quantity remaining to be exhaled 7.0 25.0-65.0 6.5
15.0 1.0-5.0 6.5
Values were computed for each of the appropriate compartments following a 6- or 8-hr exposure to 490 ppm of
benzene. To be a pass, the value of each variable at the given observation times must be within the given range
(%) of its value at the reference time (e.g., the stimulated bone marrow concentration at 0.5 hr must be within 20
to 60% of its value at 6 hr). Time is counted from the start of exposure.
goodness of fit as a way to avoid overre-
liance on highly variable experimental data,
and we now turn to the application ofthat
idea in the context of our analysis of the
Rickert and Sabourin experiments.
Because different variables were mea-
sured in each ofthese experiments at dif-
ferent times, it was clear that the criteria
for a successful simulation run would be
specific to each experiment. In general, our
criteria were stated as acceptable ranges
about the published values ofthe measured
variables at the particular times the investi-
gator chose to make the measurement.
Table 1 shows a subset ofthese criteria for
the Rickert experiment. Sixteen criteria
were used for Rickert, 15 for Sabourin
inhalation, and 16 for Sabourin gavage. In
each case, ifone ofthe criteria was met, a 1
was assigned (or a 0 if criteria were not
met). Therefore, for each of the three
experimental data sets, N Monte Carlo
simulations produced a (0,1) pass-fail
matrix of P (either 15 or 16) columns and
Nrows. To be classified as pass overall, a
simulation had to pass all the criteria for a
given experiment (i.e., for the kth simula-
tion to be a pass, all P entries in the kth
row must equal 1). Clearly, this procedure
avoids the problem noted above when
minimizing the log-likelihood measure of
goodness of fit in that each measurement
subset of the data must lie within accept-
able bounds; a very good fit to one subset
cannot compensate for a bad fit to another.
Posterior Analysis
Given the model structure, the parameter
distributions, and the outcome classification
algorithm, one can now carry out Monte
Carlo runs for either the Rickert or the
Sabourin experiments by randomly select-
ing a parameter vector, carrying out the
simulation, and classifying the result as a
pass or a fail by reference to the predeter-
mined classification rules. Repetition ofthis
process n times leads to m passing parame-
ter vectors and n - m failing vectors. The
central feature ofthe procedure is the pos-
terior analysis of the parameter vectors
using statistical procedures ofvarious sorts
to determine which elements of the para-
meter vector appear to be responsible for
passing or failing simulations. For the
moment, assume that a sufficient number
ofpasses are obtained to make this a feasi-
ble proposition.
The first step in the posterior analysis is
to inspect the univariate marginal distribu-
tions. IfF(xi) is the cumulative distribution
ofthe prior, then we ask ifthe cumulative
distributions of this parameter differ
between passing and failing simulations
(i.e., does F(xi p) = F(xi f) where p
stands for pass andffor fail?). The con-
tention is that ifdifferences can be detected
by some suitable hypothesis test, then xiis a
sensitive parameter. Ifno difference can be
detected, then multivariate analysis is
needed to further elucidate potential inter-
actions in the parameter space. (Clearly,
statistical power is also an issue, but in
Monte Carlo work, this is usually an issue
ofcost arising from model run time consid-
erations.) Figure 7 shows the cumulative
distribution ofalveolar ventilation rate for
the Sabourin inhalation data for the prior
(the dotted line) and for passing simula-
tions (the solid line). In these experiments
the number ofpassing simulations was low,
so the prior and the failing distributions are
very similar. In this particular case, the
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Figure 7. Cumulative probability plots for pass (solid)
and fail (dash) for the alveolar ventilation rate parame-
terfrom Sabourin inhalation experiment.
Wilcoxon test rejects the hypothesis that
the passing and failing distributions are
identical at the 5% level. The conclusion is
that, within the range defined by the prior
distribution, alveolar ventilation rate is a
parameter important in determining suc-
cessful from unsuccessful simulations. Over
halfof the parameters were important by
this criterion for the Rickert experiments
versus less that one-third for the two
Sabourin experiments. In retrospect, this
difference might have been expected given
the greater number ofvariables measured
by Rickert.
An interesting outcome ofthis analysis
was that, despite each ofthe parameter dis-
tributions extending over what were
thought to be biologically plausible ranges,
we found that passing simulations were not
easy to achieve. After some minor distribu-
tion trimming at the outset, we were only
able to reach 6.6% passes in the Rickert
experiment, 11% in Sabourin inhalation,
and 18.6% in Sabourin gavage. However,
passing simulations were observed over the
entire range ofparameter values allowed by
the prior distributions. This was true of
sensitive, as well as insensitive, parameters
as classified by the univariate criterion.
This led us to the conclusion that the para-
meter space is highly structured, with con-
siderable interaction between parameters.
Clearly, multivariate analysis was in order.
Multivariate Analysis
Only one ofthe various multivariate analy-
ses that we carried out will be described
because it goes directly to the metanalysis
idea. In particular, if the model structure
and parameter distributions were com-
pletely consistent over all three data sets,
then a statistical analysis ofpassing parame-
ter vectors should be able to discern no dif-
ferences in those multivariate distributions
by experiment. That is, a parameter vector
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Figure 8. CART diagram from three experiments. Node
1 contains just passes, 307 from the Rickert experiment,
172 from the Sabourin inhalation experiment, and 174
from the Sabourin gavage experiment. After splitting on
parameters Fa5v and Fpp, Node 2 contains no Rickert
passes. A split using Falv and Kml leads to Node 4 con-
taining most of the Sabourin inhalation passes and
Node 5containing most ofthe Sabourin gavage passes.
giving rise to a successful simulation ofthe
Rickert data should give rise to a successful
simulation of the Sabourin experiments.
We subjected the passing parameter vectors
from the three experiments to analysis by a
procedure called Classification and
Regression Trees (CART). CART a com-
puter-intensive multivariate analysis pro-
gram which, in this application, attempts to
find rules based on the parameter values
which associate the parameter vector with a
particular experiment.
Figure 8 shows the outcome of the
CART run in which the program was chal-
lenged with finding parameter-based rules
for classifying a vector as coming from the
Rickert, Sabourin gavage, or Sabourin
inhalation experiments. The analysis begins
at node 1 with 307 Rickert passing vectors,
172 Sabourin inhalation passes and 174
Sabourin gavage passes. The first rule the
program determined was based on a linear
combination ofalveolar ventilation rate and
blood flow through the poorly perfused tis-
sue, Fp. (It is interesting to note that F.,
was nor identified as an important variable
in any ofthe univariate analyses.) Ifthe cri-
terion was not met, then all 307 Rickert
vectors were sent to node 3 with 1 Sabourin
inhalation and 29 Sabourin gavage vectors.
Clearly, these two parameters alone
identified the Rickert vectors with very low
misclassifications of the Sabourin vectors.
Most ofthe Sabourin vectors were sent to
node 2, where a second rule was determined
based again on alveolar ventilation, but this
time, coupled with the K value in the
liver. This rule does a good job ofseparat-
ing the Sabourin inhalation vectors, node 4,
from the gavage vectors, node 5.
The final outcome of this multivariate
analysis was that, on the basis ofonly three
of the 26 parameters, CART could deter-
mine portions ofthe parameter space pref-
erentially associated with each of the
experiments. Various explanations spring
to mind, but we note that one inhalation
experiment used exposure chambers and
the other a nose-mask administration sys-
tem. Also, the Rickert and Sabourin experi-
ments were performed at different altitudes
and other aspects of the protocols and
methods differed. Nevertheless, the ease
with which CART was able to discern that
differences existed was disconcerting.
Clearly, the model is not consistent across
these three sets ofexperimental data.
Methodological versus
Biological Accomplishments
At this point it is interesting to reflect on
what had been accomplished in this project
in late 1990, when much ofthe foregoing
work was completed. In particular, it is
interesting to contrast the methodological
viewpoint with the biological. In the former
area, we were all surprised at how few pass-
ing simulations we obtained, particularly in
view ofthe fact that we were dealing with a
PBPK model with the advantage ofassign-
ing to the parameter distributions only
what the literature suggested to be biologi-
cally plausible values. Second, it seemed
curious that passing simulations extended
to virtually all corners of the parameter
hypercube. There was no suggestion of
whatwe called "raisins in the pudding," iso-
lated areas in the parameter space with a
high density ofpasses. Rather, the results
suggested a n-dimensional ribbon winding
around in the parameter space. We have
seen a very similar picture in a large ecosys-
tem model that we are working with, as
well as in a model ofmosquito population
dynamics in the context ofarboviral disease
transmission. It is somewhat difficult to dis-
cern anything definitive about the shape of
the passing region in 26 dimensions with
the very sparse number ofpoints available,
but it is clear that there must be a great deal
of interaction between parameters if a par-
ticular parameter can take on any value in
its range yet still achieve a pass ifother para-
meters are in the right place. We are only
now beginning to mount a more sophisti-
cated approach to investigating these com-
plicated interactions in high-dimensional
spaces. If one were to have a model that
would extend from distribution and metab-
olism through to cellular damage, an under-
standing of these high-dimensional
interactions would hold the key to under-
standing the importance ofexposure-related
parameters versus genetically determined
parameters in the production ofchemically
related disease.
Turning to the interests ofour labora-
tory-based colleagues, the situation was very
different. They had little interest in the
work described above. Indeed, much ofthis
work had been concerned with the develop-
ment ofmodels that had modest potential
to address issues ofinterest to them. Their
interest is in mechanism oftoxic action and
it was clear that, at the very least, we had to
be able to model metabolic processes to
stimulate any interest at all. The stimulus to
develop such a model arose in the context
of the carcinogenic properties of benzene
versus phenol. Benzene is pan-carcinogenic
in animals, while phenol did not exhibit
carcinogenic effects during its National
Toxicology Program (NTP) study (9).
However, phenol is on the pathway from
benzene to some of the suspected ultimate
carcinogens (hydroquinone and benzo-
quinone). On the basis of that argument,
phenol should be a carcinogen, unless
extensive first-pass effects prevent it from
entering the general blood circulation. The
challenge was to produce a model that was
consistent with what was known on the dis-
tribution and metabolism ofboth benzene
and phenol and then to determine which
metabolic products showed major differ-
ences under the conditions of the NTP
bioassays (gavage for benzene and drinking
water exposure for phenol). We wanted, in
particular, to assess whether a much larger
quantity ofhydroquinone had been formed
during benzene exposure than during phe-
nol exposure. Such a model was developed
that tracked circulating levels of benzene
and phenol and the production of the
major metabolites (10). Figure 9 shows the
metabolic pathways described by the model.
This is the most complete model ofbenzene
metabolism published to that time. It uses
the benzene distribution model (Figure 1)
and a second model describing the distribu-
tion ofphenol in the body. Clearly this was
a complicated model with 12 compart-
ments and 64 parameters. Calibrating it to
the pharmacokinetic and metabolic data at
hand was a challenging task. We again used
Monte Carlo simulations and reverted to a
continuous measure offit, log-likelihood,
which has several disadvantages as men-
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Figure 9. Our latest model of benzene metabolic path-
ways. MM, Michaelis-Menten reactions.
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Figure 10. Predictions made by the best-fitting simu-
lation run versus observed experimental values
(3,4,11-13). For a perfect fit, the points would fall on
the identity line.
tioned above, but could lead quickly to
improvement in the goodness offit. Figure
10 shows the quality of fit of the best
Monte Carlo simulation (after some 3000
runs).
As shown in Figure 11, the predicted
levels ofphenol and hydroquinone circu-
lating or formed during the phenol-NTP
cancer bioassay were higher than during
the benzene bioassay. This is in direct
conflict with the hypothesis that phenol or
hydroquinone are solely responsible for
benzene carcinogenicity. By contrast, cate-
chol and muconaldehyde were formed dur-
ing benzene administration, but to a much
lesser degree during phenol administration.
We had to conclude that hydroquinone
alone is unlikely to be the ultimate carcino-
gen. Other lines ofevidence (from in vitro
mutagenicity tests) points also to a synergy
between the various metabolites.
More recently, this model was
employed in a straightforward risk assess-
ment mode to explore whether peak expo-
sures to benzene are potentially more
p.00
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Figure 11. Predicted quantities of various metabolites
formed during a week of either benzene exposure (first
box of each pair, lowes gavage dose in the National
Toxicology Program experiment) or phenol exposure
(second boxes, highest drinking water in the NTP
experiment). Symbols: bx, benzene oxide; phen, phenol
(concentration in blood, not quantity formed); pma,
phenyl mercapturic acid; hq, hydroquinone; cat, cate-
chol; muc, muconaldehyde.
damaging than constant exposures in the
occupational environment (11). The
model was parameterized using Monte
Carlo simulations as described previously.
The 200 sets ofparametervalues giving the
best fits were then used to predict the
amount of metabolites formed in 24 hr
after inhalation exposure to either 1 ppm
for 8 hr or 32 ppm for 15 min. Note that
these two exposure schedules lead to the
same total inhaled dose and hence have the
same 8-hr time-weighted average. Under
linear behavior, as has traditionally been
assumed when assessing the risk ofbenzene
carcinogenesis, the total amount of each
metabolite formed would be the same for
both exposures. However, results showed
that for some metabolites, including the
most toxic, there is a 20% difference, on
average, between the amount ofmetabolite
produced under peak versus constant expo-
sure conditions (Figure 12). Therefore, at
low levels, benzene peak exposures poten-
tially are more detrimental than constant
ambient concentrations. At high levels, as
in controlled experiments, this effect is not
observed. Thus, our conclusions, most rele-
vant to human exposure levels, were only
accessible through model extrapolation and
not through experimentation alone. This
modeling approach can be applied to
obtain correct estimates ofeffective expo-
sure for various cohorts ofoccupationally
exposed individuals.
Conclusions
Ourworkhas had three major components:
methodological issues surrounding the
parameterization and use ofcomplicated
models, the use ofthe benzene models in
the formulation and analysis ofhypotheses
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Figure 12. Box plots of the relative differences in the
formation of various benzene metabolites in rats after
exposures to 1 ppm for 8 hr or 32 ppm for 15 min.
These results were obtained by simulation.
regarding toxic mechanisms, and the use of
the benzene models in risk assessment
applications. While our applications ofthe
models have been similar to many other
applications ofPBPK models, our method-
ological approach has some unique features.
The obvious question concerns what
insights we may have gained that can be
attributed to the use ofthe more compli-
cated Monte Carlo methods we have
employed. Although the point was not
emphasized above, we have no doubt that
the use ofparameter distributions and the
pass-fail fit criterion lead to a robust form
ofsensitivity analysis that has significant
advantages in these applications over the
fixed-parameter perturbation methods con-
ventionally employed. The principal advan-
tage ofour approach is that it acknowledges
that, in most biological applications, there
is no clearlydefensible way to select a "best"
set ofparameters about which to carry out
traditional sensitivity analysis.
Indeed, the advantage offered by the
Monte Carlo approach does seem to relate
generally to the notion of robustness in
avoiding overreliance on particular parame-
ter values in the absence ofvery compelling
and specific data defining their population
distribution. In all ofthe foregoing analy-
ses our conclusions rested not on a single
set ofmodel parameters, but numerous sets
whose values vary extensively over biologi-
cally plausible values. Our conclusions
relate to the behavior of the model over
regions ofthe parameter space rather than
at a single point. Returning to Figure 11,
for example, the rejection ofhydroquinone
as the ultimate carcinogen is based on the
fact that the hydroquinone distribution
under phenol administration generally
exceeds that ofthe corresponding distribu-
tion under benzene administration.
Clearly, there are pairs ofindividual simu-
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lations, both ofwhich give rise to good fits
to the experimental data, where the pro-
duction ofhydroquinone was two orders of
magnitude greater in the benzene experi-
ment than in the phenol experiment and
vice versa. That is, there are particular sets
of parameter values that would produce
simulation results supporting either the
conclusion that hydroquinone is important
or that it is not. Looked at from the per-
spective ofthe totality ofacceptable simu-
lations, however, the pathway through
benzene glycol to catechol and muconalde-
hyde looks much more likely.
In the context of risk assessment too,
there is much to be said for taking a distrib-
utional view rather than focusing on point
estimates of the risk of the most exposed
individual. Here the context is somewhat
different, but the underlying variability in
population susceptibility or in the uncer-
tainty of our knowledge ofparameter val-
ues is just as much ofa problem and has
just as great a potential for leading to inap-
propriate risk management decisions.
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